120
Participants
Start Date
July 31, 2010
Primary Completion Date
October 31, 2012
Study Completion Date
November 30, 2012
CDX-011
CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
"Investigator's Choice chemotherapy"
Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
Weill Cornell Breast Center/Weill Cornell Medical College, New York
Montefiore-Einstein Cancer Center, The Bronx
Clinical Research Alliance Inc., Lake Success
Guthrie Clinic, Ltd., Sayre
Levine Cancer Institute/Blumenthal Cancer Center, Charlotte
Santee Hematology Oncology, Inc., Sumter
South Carolina Oncology Associates, Columbia
Peachtree Hematology-Oncology Consultants PC, Atlanta
Georgia Cancer Specialists, Atlanta
The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
Sarah Cannon Research Institution, Nashville
Center for Biomedical Research, Knoxville
Oncology Hematology Care, Cincinnati
Henry Ford Health System, Detroit
Montana Cancer Institute Foundation, Missoula
Orchard Healthcare Research Inc., Skokie
Cancer Treatment Centers of America at Midwestern Regional Medical Center, Zion
Cancer Care of Louisiana, New Orleans
Arizona Cancer Center, Tucson
The Angeles Clinic and Research Institute, Los Angeles
USC/Norris Comprehensive Cancer Center, Los Angeles
Breastlink Medical Group, Long Beach
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Florida Cancer Specialists, West Coast
Lead Sponsor
Celldex Therapeutics
INDUSTRY